Cyclacel Pharmaceuticals (CYCC) - התחייבויות לטווח ארוך להון

Cyclacel Pharmaceuticals (CYCC) is developing a pipeline of high-precision treatments for leukemias and solid tumors through cell cycle control. The company is fostering synergy with research centers to accelerate the time-to-market for its drugs. Under Spiro Rambalakos's leadership, the company maintains a strict austerity policy while awaiting test data, with the indicator standing at 0.00. The market trend for the asset shown on this price chart reflects the dynamics of debt obligations and equity.

This indicator assesses the cost of servicing long-term liabilities relative to the company's equity. Analyzing the ratio of long-term loans to equity allows for the determination of the degree of financial leverage. The metric is calculated by dividing the total amount of loans with a maturity of more than one year by the value of net assets. For Cyclacel Pharmaceuticals (CYCC), a low level of borrowing minimizes the risk of cash flow gaps. This ensures stable funding for multi-year anti-cancer drug development and the protection of the patent portfolio.